Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 343 resultados
LastUpdate Última actualización 03/08/2026 [08:30:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 175 a 200 de 343 nextPage  

TRIPLE TISSUE CULTURE FUSION

NºPublicación:  US20260185056A1 02/07/2026
Solicitante: 
IMBA INST FUER MOLEKULARE BIOTECHNOLOGIE GMBH [AT]
IMBA - INSTITUT F\u00DCR MOLEKULARE BIOTECHNOLOGIE GMBH
US_20260185056_A1

Resumen de: US20260185056A1

An in vitro method of producing a fused tissue culture with at least three different tissues including selecting a spatial shape for attaching the at least three different tissues to each other, placing the at least three different tissues into contact in the spatial shape, culturing the at least three different tissues under conditions that maintains tissue fusion of the at least three different tissues is disclosed. Further provided is a tissue culture comprising a planar or linear fusion of at least three different neural or neuronal tissues, uses thereof and means for its production.

PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE

NºPublicación:  US20260184772A1 02/07/2026
Solicitante: 
AXON NEUROSCIENCE SE [CY]
AXON NEUROSCIENCE SE
US_20260184772_A1

Resumen de: US20260184772A1

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

タンパク質コロナ中のタンパク質を検出するための組成物および方法

NºPublicación:  JP2026521420A 30/06/2026
Solicitante: 
ボードオブトラスティーズオブミシガンステートユニバーシティ
JP_2026521420_A

Resumen de: CN121263693A

Provided herein are methods for detecting proteins and/or protein variants thereof, the methods comprising adding to a biological sample one or more small molecules and one or more protein binding agents wherein a protein crown is formed on a surface of the protein binding agent, and detecting the protein and/or protein variants thereof in the protein crown by antibody-based technology or proteomic technology. Also provided herein are methods for detecting one or more biomarkers or patterns of one or more biomarkers associated with a disease or health profile condition, as well as methods of diagnosing or predicting a disease in a subject. Compositions comprising one or more small molecules, one or more protein binding agents, and one or more biological samples are also provided.

缩醛磷脂的定量方法及缩醛磷脂定量用试剂盒

NºPublicación:  CN122319365A 30/06/2026
Solicitante: 
株式会社食物流变功能研究所国立大学法人九州大学
CN_122319365_PA

Resumen de: WO2025146757A1

This method for quantifying plasmalogens comprises: a measurement sample preparation step for mixing a Schiff reagent with a specimen containing protein and plasmalogens to obtain a measurement sample; a control sample preparation step for mixing the specimen with a solvent of the Schiff reagent to obtain a control sample; a measurement step for measuring the extent of a first optical property of the measurement sample, the first optical property being obtained by reacting the Schiff reagent with an aldehyde generated from vinyl ether bonds of the plasmalogens, and measuring the extent of the optical property of the control sample; and a determination step for determining the concentration of plasmalogens in the specimen by comparing the correction extent, that is the extent to which the extent of the first optical property has been corrected by the extent of the optical property of the control sample, with the extent of a second optical property of a standard sample containing the Schiff reagent and a known concentration of plasmalogens, the second optical property being the optical property after the Schiff reagent has been reacted with the aldehyde generated from the vinyl ether bonds of the plasmalogens.

Spectroscopic substrate for dementia diagnosis comprising hydrophilized graphene layer and spectroscopy device comprising the same

NºPublicación:  KR20260101594A 30/06/2026
Solicitante: 
국일그래핀주식회사허채정
KR_20260101594_PA

Resumen de: KR20260101594A

본원은 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다. 더욱 상세하게, 본원은 아밀로이드 베타와의 결합력 및 선택성 증가로 정확도가 개선된 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다.

Aβ寡聚体作为生物标志物在制备轻度认知障碍风险评估产品中的用途

NºPublicación:  CN122307115A 30/06/2026
Solicitante: 
上海市精神卫生中心(上海市心理咨询培训中心)
CN_122307115_PA

Resumen de: CN122307115A

本发明提供一种生物标志物在制备轻度认知障碍风险评估产品中的用途,所述生物标志物包括Aβ寡聚体。单独的Aβ寡聚体标志物对MCI具有显著的预测价值,在区分认知正常与MCI的受试者时,其测试集受试者工作特征曲线下面积(AUC)即可达到 0.851(95% 置信区间:0.803 ‑ 0.895),证明其在区分出MCI受试者具有优越的性能。

乳酰化修饰PRDX5蛋白及其产品和应用

NºPublicación:  CN122297687A 30/06/2026
Solicitante: 
吉林大学
CN_122297687_PA

Resumen de: CN122297687A

0001 本发明提供了乳酰化修饰PRDX5蛋白及其产品和应用,属于生物医药技术领域。本发明揭示了PRDX5 K71位点乳酰化修饰在COPD病理进程中的关键作用,其在COPD小鼠海马组织神经元乳酰化水平异常升高,且与小鼠认知功能障碍的发生发展密切相关;同时提供了靶向该位点的特异性干预方案,通过立体定位注射重组腺相关病毒PRDX5 K71R突变体降低或阻断K71位点发生乳酰化修饰的可能性,可有效改善COPD小鼠的学习记忆与空间定位能力,为认知功能障碍的机制研究与靶向防治提供了新的分子靶点和实验依据。

神经退行性变标志物检测试剂及检测方法

NºPublicación:  CN122307112A 30/06/2026
Solicitante: 
科美诊断技术股份有限公司
CN_122307112_A

Resumen de: CN122307112A

0001 本申请涉及一种神经退行性变标志物检测试剂及检测方法。该神经退行性变标志物检测试剂包括产氧剂、催化剂和能够与待测样本中的待测神经退行性变标志物特异性结合的免疫检测试剂;其中,产氧剂在催化剂的作用下发生反应生成氧气,生成的氧气用于增加反应体系中的氧含量;免疫检测试剂能够利用反应液中的活性氧产生光信号,待测靶分子选自神经退行性变标志物。本申请提供的方案,能够在神经退行性变标志物浓度水平较低时,提高光信号值,有利于提高对神经退行性变标志物的检出能力。

前脳基底部コリン作動性神経細胞(BFCN)を生成するための方法および組成物

NºPublicación:  JP2026108846A 30/06/2026
Solicitante: 
ニューヨークステムセルファウンデーションインコーポレイテッド
JP_2026108846_A

Resumen de: WO2018218193A1

The invention relates to methods and compositions for developing basal forebrain cholinergic neurons (BFCNs) from stem cells, and in particular, BFCNs having repaired electrophysiological defects relating to one or more mutations in PSEN2, and to the use of such BFCNs in cell-based therapies to treat Alzheimer's disease.

NUCB1在预防和/或治疗自身免疫性疾病中的应用

NºPublicación:  CN122297639A 30/06/2026
Solicitante: 
中国科学院分子细胞科学卓越创新中心苏州一弹生物有限公司
CN_122297639_A

Resumen de: WO2026145099A1

Provided in the present invention is the use of NUCB1 in the prevention and/or treatment of autoimmune diseases. Specifically provided in the present invention is the use of an NUCB1 gene, or a protein thereof, or a promoter thereof in the preparation of a composition or preparation, wherein the composition or preparation is used for preventing and/or treating autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof of the present invention can significantly prevent and/or treat autoimmune diseases, and is particularly effective against systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis, or Crohn's disease.

一类含有2,4-噻唑环的化合物在抗衰老中的应用

NºPublicación:  CN122297477A 30/06/2026
Solicitante: 
山东大学
CN_122297477_PA

Resumen de: CN122297477A

0001 本发明涉及生物医药领域,公开了一种含有2,4‑噻唑环的化合物在抗衰老中的应用。含有2,4‑噻唑环的化合物为式X所示化合物或其药学上可接受的盐,其中式X化合物包括具有吡唑并嘧啶骨架的式I类化合物和具有吲哚骨架的式II类化合物。本发明人首次发现IL4I1是调控细胞衰老的关键分子,并阐明了式X化合物通过靶向IL4I1,解除IL4I1对EIF4B的泛素化降解,上调EIF4B‑PGAM5轴表达,从而维持线粒体稳态、延缓细胞及组织衰老的作用机制。实验结果表明,本发明所述含有2,4‑噻唑环的化合物可有效预防放化疗诱导的细胞衰老,减轻放疗诱导的小鼠整体衰老,改善运动功能,降低衰老相关分泌表型因子分泌,缓解器官纤维化。本发明为开发新型抗衰老药物提供了新的化学分子基础和作用靶点。

DNA Aptamer Specifically Binding to alpha-synuclein protein and Uses Thereof

NºPublicación:  KR20260100566A 30/06/2026
Solicitante: 
CHUNGBUK NATIONAL UNIV INDUSTRY ACADEMIC COOPERATION FOUNDATION [KR]
\uCDA9\uBD81\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8
KR_20260100566_PA

Resumen de: KR20260100566A

본 발명은 알파-시누클레인 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 서열번호 1 내지 12의 염기서열로 이루어진 군 중에서 선택되는 알파-시누클레인(α-synuclein) 단백질에 특이적으로 결합하는 DNA 앱타머(aptamer), 상기 앱타머를 유효성분으로 포함하는 알파-시누클레인 단백질 검출용 조성물, 검출용 키트, 검출용 칩 또는 마이크로어레이에 관한 것이며, 또한 본 발명은 본 발명의 DNA 앱타머를 이용한 알파-시누클레인 단백질의 검출방법, 퇴행성 뇌질환의 진단을 위한 정보 제공 방법, 퇴행성 뇌질환의 진단용 조성물 및 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물에 관한 것이다.

疾患および障害の検出のために細胞外小胞を使用する方法および組成物

NºPublicación:  JP2026108857A 30/06/2026
Solicitante: 
パールダイアグノスティクス,インコーポレイティド
JP_2026108857_A

Resumen de: AU2020258381A1

Disclosed herein are methods for detecting a biological or chemical entity in a sample, wherein the biological or chemical entity is associated with extracellular vesicles. The methods disclosed comprise the steps of a) processing the sample, (b) using a detection assay to detect the presence of extracellular vesicles and to isolate the extracellular vesicles, (c) processing the extracellular vesicles to expose or release the biological or chemical entity, and (e) detecting the biological or chemical entity released from the extracellular vesicle. In certain embodiments, the extracellular vesicles are associated with proteins, glycoproteins, peptides, lipids, nucleic acids or other cellular components. The detection methods are useful for identifying the presence of microbial antigens related to

IMAGING SYSTEM HARDWARE

NºPublicación:  US12668835B1 30/06/2026
Solicitante: 
10X GENOMICS INC [US]
10x Genomics, Inc.
US_12668835_B1

Resumen de: US12668835B1

A sample holder includes a first member featuring a first retaining mechanism configured to retain a first substrate that includes a sample, a second member featuring a second retaining mechanism configured to retain a second substrate that includes a reagent medium, and an alignment mechanism connected to at least one of the first and second members, and configured to align the first and second members such that the sample contacts at least a portion of the reagent medium when the first and second members are aligned.

胆碱仿生双亲聚合物纳米盘及其制备方法和应用

NºPublicación:  CN122302156A 30/06/2026
Solicitante: 
烟台新药创制山东省实验室
CN_122302156_PA

Resumen de: CN122302156A

0001 本发明提供一种胆碱仿生双亲聚合物纳米盘,所述胆碱仿生双亲聚合物纳米盘的制备原料包括聚甲基丙烯酸酯共聚物;所述聚甲基丙烯酸酯共聚物由2‑甲基丙烯酰氧乙基磷酰胆碱与甲基丙烯酸己酯经聚合反应制备得到。该胆碱仿生双亲聚合物纳米盘具备高效穿越BBB的能力和脑靶向能力,在体外BBB模型和小鼠体内都能高效的通过胆碱转运受体跨越BBB,该胆碱仿生双亲聚合物纳米盘的盘状形态和纳米级尺寸促进了血管、基质和细胞屏障的有效渗透,具有卓越的实体瘤浸润能力。本发明提供一种上述的胆碱仿生双亲聚合物纳米盘的制备方法以及上述的胆碱仿生双亲聚合物纳米盘在制备脑肿瘤的检测试剂或脑肿瘤的预防、治疗药物中的应用。

Kits and detection method for diagnosis of Parkinson's disease and Synucleinopathy

NºPublicación:  KR20260099247A 29/06/2026
Solicitante: 
PEOPLEBIO INC [KR]
\uC8FC\uC2DD\uD68C\uC0AC \uD53C\uD50C\uBC14\uC774\uC624
KR_20260099247_PA

Resumen de: KR20260099247A

본 발명은 파킨슨병 및 시누클레인병증 진단을 위한 키트 및 검출 방법에 관한 것이다. 본 발명의 키트 및 검출 방법을 이용하면 환자의 혈장을 이용하여 비침습적이면서도 높은 정확도를 가지고 파킨슨병과 시누클레인병증을 진단할 수 있다.

一种基于不良结局路径模型的污染物联合暴露毒性风险预警方法及系统

NºPublicación:  CN122291031A 26/06/2026
Solicitante: 
上海海洋大学
CN_122291031_PA

Resumen de: CN122291031A

0001 本发明公开了一种基于不良结局路径模型的污染物联合暴露毒性风险预警方法,建立联合暴露体系,将受试对象分为空白对照组、单一污染物暴露组及联合暴露组,在预设环境条件下进行暴露;在暴露过程中设置两个采样时间点,包括第一采样时间点和第二采样时间点;获取受试对象多层级检测指标数据,包括生化指标、组织病理指标、表面超微结构指标和/或基因表达指标;基于所述多层级检测指标数据,识别不良结局路径中的分子起始事件、早期关键事件、后期关键事件及不良结局,建立分子起始事件至关键事件再至不良结局的因果关联链条;根据不良结局的出现情况,输出分级风险预警结果。联合暴露体系中的受试对象为鱼类,污染物为全氟辛酸和聚苯乙烯微塑料。

用于完整脑组织内大规模电生理动力学和转录谱的高分辨率空间和时间映射的方法和装置

NºPublicación:  CN122295573A 26/06/2026
Solicitante: 
德国神经退行性疾病中心
CN_122295573_PA

Resumen de: EP4560314A1

0001 The present invention relates to an ex vivo method for mapping the spatiotemporal electrophysiological dynamics and spatial transcriptional profiles of cells in a functional neuronal cell assembly, comprising simultaneous recording and analysis of spatial data of molecular and electrical network activity down to the level of individual cells using high-density electrical biosensors, spatial transcriptomics, optical imaging, and advanced computational strategies. The invention further relates to methods for identifying the composition of a functional neuronal assembly, for monitoring the spatiotemporal electrophysiological dynamics and transcriptional profiles of cells in a functional neuronal cell assembly, for monitoring the cellular composition of a functional neuronal assembly, or for identifying a compound having an effect on the spatial electrophysiological and transcriptional dynamics and/or for identifying the composition of cells in a functional neuronal cell assembly based on the dynamics as detected, as well as devices and uses thereof. The invention allows for a better understanding of disease mechanisms, and to find therapeutic targets and to develop new drugs and treatments.

一种用于阿尔茨海默病早期筛查的泪液检测装置及方法

NºPublicación:  CN122283142A 26/06/2026
Solicitante: 
重庆工商大学
CN_122283142_PA

Resumen de: CN122283142A

本发明公开了一种用于阿尔茨海默病早期筛查的泪液检测装置及方法,属于体外诊断医疗器械技术领域,包括泪液采样器、微流控芯片和便携式读数器,泪液采样器用于将采集并预处理的泪液样本输送至微流控芯片,微流控芯片上设置有样品输入口,泪液采样器与样品输入口连接,微流控芯片上设置有用于检测生物标志物的微通道结构,且微流控芯片能置于便携式读数器的卡槽内,便携式读数器用于进行信号检测并对监测数据进行分析后输出诊断结果。本发明采用上述的一种用于阿尔茨海默病早期筛查的泪液检测装置及方法,旨在实现阿尔茨海默病的早期、快速、高灵敏度诊断。

一种磷酸化Tau181蛋白测定试剂盒及应用

NºPublicación:  CN122283145A 26/06/2026
Solicitante: 
广州瑞辉生物科技股份有限公司
CN_122283145_A

Resumen de: CN122283145A

本发明属于检测技术领域,本发明具体公开了一种磷酸化Tau181蛋白测定试剂盒及应用,本申请所述的抗试剂A和抗试剂B中的p‑Tau181抗体中的生物素和碱性磷酸酶发生反应,形成抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的反应结合到磁性微粒上,加入化学发光底物AMPPD,碱性磷酸酶催化AMPPD产生化学发光信号,通过光学检测系统测量发光强度,仪器自动通过工作曲线计算得出检测结果,本申请通过对试剂盒的抗试剂A和抗试剂B以及磁微粒试剂进行设计,能够精准捕获抗体并放大信号,有效的降低检测限,提升试剂盒的综合性能。

神经轻链蛋白的检测试剂盒、方法及磁性水凝胶制备方法

NºPublicación:  CN122283116A 26/06/2026
Solicitante: 
甘肃省科学院传感技术研究所
CN_122283116_PA

Resumen de: CN122283116A

本发明公开了一种神经轻链蛋白的检测试剂盒、方法及磁性水凝胶制备方法,本发明的检测试剂盒,包含磁性水凝胶偶联探针,神经轻链蛋白检测抗体,预激发液和激发液;其中,磁性水凝胶偶联探针为表面络合有顺磁性的纳米四氧化三铁粒子的含羧基聚合物球形颗粒。

一种检测载脂蛋白E4的抗体及其应用

NºPublicación:  CN122277723A 26/06/2026
Solicitante: 
东莞市朋志生物科技有限公司
CN_122277723_A

Resumen de: CN122277723A

0001 本发明公开了检测载脂蛋白E4的抗体及其应用,具体涉及检测阿尔茨海默症血液标志物ApoE4的检测抗体和试剂盒,基于该抗体及试剂盒能够准确的检测载脂蛋白E4的存在。

抗NFL蛋白的单克隆抗体组合及其用途

NºPublicación:  CN122277725A 26/06/2026
Solicitante: 
华南理工大学
CN_122277725_PA

Resumen de: CN122277725A

本申请实施例提供了一种抗NFL蛋白的单克隆抗体组合及其用途。所述单克隆抗体组合包括第一抗体和第二抗体,第一抗体包括第一重链可变区和第一轻链可变区,第二抗体包括第二重链可变区和第二轻链可变区;第一重链可变区包括如SEQ ID NO:3‑5所示的三个互补决定区,第一轻链可变区包括如SEQ ID NO:6‑8所示的三个互补决定区;第二重链可变区包括如SEQ ID NO:11‑13所示的三个互补决定区;第二轻链可变区包括如SEQ ID NO:14‑16所示的三个互补决定区。本实施例提供的单克隆抗体组合具有优异的特异性和高亲和力,可用于体外定量检测血清中NFL浓度,为神经系统相关疾病的辅助诊断提供技术支持。

タンパク質-タンパク質相互作用を誘導するための化合物を同定する方法

NºPublicación:  JP2026521202A 26/06/2026
Solicitante: 
オンコピアセラピューティクスインコーポレイテッドディー/ビー/エーエスケーライフサイエンスラボズ
JP_2026521202_A

Resumen de: AU2024312747A1

The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.

FSTL1蛋白作为特发性正常压力脑积水标记物的应用及检测方法

Nº publicación: CN122283146A 26/06/2026

Solicitante:

青岛大学附属医院

CN_122283146_PA

Resumen de: CN122283146A

0001 本发明提供了人源卵泡抑素样蛋白(FSTL1)作为特发性正常压力脑积水标记物的应用及检测方法及试剂盒,其中,人源卵泡抑素样蛋白(FSTL1)的NCBI Gene ID 11167,RefSeq mRNA编号为NM_007085.5,RefSeq蛋白编码为NP_009016.1,UniProt编号为Q12841。本发明解决了现有检测技术中存在的无法早期分子识别、标志物特异性不足、低丰度蛋白检测灵敏度不足的技术问题。

traducir